Featured Press Releases

Axonal.AI launches an industry-first platform to accelerate life sciences time to market

Axonal.AI launches an industry-first platform to accelerate life sciences time to market

PBS Biotech Secures $17M and Expands Leadership to Accelerate Next-Gen Cell Therapies

PBS Biotech Secures $17M and Expands Leadership to Accelerate Next-Gen Cell Therapies

  • 06 Jan 2025

PBS Biotech ("PBS"), a provider of innovative single-use bioreactor systems and bioprocess...

Octapharma Announces Availability of Balfaxar® For Warfarin Reversal in Urgent Surgery & Invasive Procedures

Octapharma Announces Availability of Balfaxar® For Warfarin Reversal in Urgent Surgery & Invasive Procedures

Orthofix Receives FDA 510(k) Clearance for Rodeo™ Telescopic Nail

Orthofix Receives FDA 510(k) Clearance for Rodeo™ Telescopic Nail

Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research

Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research

To expand biopharma services with its liquid biopsy capabilities, Precision for Medicine partners with SOPHiA GENETICS on the SOPHiA DDM™ platform

To expand biopharma services with its liquid biopsy capabilities, Precision for Medicine partners with SOPHiA GENETICS on the SOPHiA DDM™ platform

Stablepharma Launches Phase 1 Trials for First-Ever Fridge-Free Tetanus & Diphtheria Vaccine

Stablepharma Launches Phase 1 Trials for First-Ever Fridge-Free Tetanus & Diphtheria Vaccine

  • Stablepharma Ltd
  • 30 Apr 2025
Xencor Announces Promising Early Results for XmAb942 in First-in-Human Study Targeting IBD

Xencor Announces Promising Early Results for XmAb942 in First-in-Human Study Targeting IBD

  • XENCOR, Inc.
  • 29 Apr 2025
Bold Therapeutics Presents Late-Breaking Data on BOLD-100’s Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN)

Bold Therapeutics Presents Late-Breaking Data on BOLD-100’s Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN)

  • Bold Therapeutics Inc.
  • 28 Apr 2025
At the Longhorn Vaccines and Diagnostics Presents Compelling Data on the LHNVD-303 Vaccine for Sepsis Linked to Bacterial Infections

At the Longhorn Vaccines and Diagnostics Presents Compelling Data on the LHNVD-303 Vaccine for Sepsis Linked to Bacterial Infections

  • Longhorn Vaccines and Diagnostics
  • 28 Apr 2025
Innorna Announces FDA Grants Rare Pediatric Disease and Orphan Drug Designations to IN013 for Wilson Disease Treatment

Innorna Announces FDA Grants Rare Pediatric Disease and Orphan Drug Designations to IN013 for Wilson Disease Treatment

  • Innorna Co. Ltd.
  • 28 Apr 2025
Delcath Systems Receives FDA Clearance for IND Application to Begin Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Delcath Systems Receives FDA Clearance for IND Application to Begin Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

  • Delcath Systems, Inc.
  • 28 Apr 2025

Most Popular
May   2025
M T W T F S S
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31  

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.